However, when FOXO1 siRNA-MDS-L cells were treated with DAC, the observed increase in CD3-positive cells were significantly reduced compared to cells bearing negative control siRNA (Figure 5C), indicating that silencing FOXO1 before DAC treatment weakens, but does not eliminate the differentiation of DAC-induced MDS-L cells into antigen molecules. The gene discussed is FOXO1; the disease is myelodysplastic syndrome.